Navigation Links
Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
Date:3/14/2012

SAN MATEO, Calif., March 14, 2012 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced the schedule of its upcoming presentation of clinical data at the American College of Cardiology (ACC) 61th Scientific Session, March 24-26th. Location: McCormick Place South, Hall A Date: Monday, March 26, 2012 Time: 10:00 AM -12:00 PM (CT) Poster Presentation: Board #628  Presenter: Hsiao D. Lieu, MD, FACC Title: "Initial Experience with Subcutaneous Infusion of Cenderitide in Patients with Chronic Heart Failure"About Heart FailureHeart failure is the fastest-growing clinical cardiac disease in the U.S. according to the American Heart Association, affecting over 5 million Americans. Over 1 million patients in the U.S. each year are hospitalized with ADHF, an acute exacerbation of heart failure. ADHF is the is the most frequent cause of hospital admission in the U.S. for patients older than 65 years, generating annual inpatient costs of more than $35 billion. Within 90 days following admission for ADHF, approximately 40% of patients return to the hospital. Nile believes that a decrease in the ADHF re-hospitalization rate, which is the clinical target of the cenderitide development program, could both improve the quality of life for patients and decrease the annual inpatient cost of heart failure.

About Nile TherapeuticsNile Therapeutics, Inc. is a biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. The cenderitide program was granted Fast Track status by the United States Food and Drug Administration. More information on Nile can be found at http://www.nilethera.com.


'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prime Therapeutics Announces CareCentered Contract™ with EMD Serono, Inc. for MS Drug Rebif®
2. ADHD Therapeutics Reviewed by NeuroPerspective
3. Cell Therapeutics, Inc. (CTI) Reports Fourth Quarter and Year-End Financial Results and Milestones
4. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2011 Financial Results on March 7
5. Particle Sciences Acquires Exclusive License to Lyotropic Therapeutics Drug Delivery Technology
6. Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results
7. Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million
8. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
9. Amsterdam Molecular Therapeutics Receives Request for Further Information From CHMP on Glybera®
10. Compendia Bioscience and H3 Biomedicine Announce Strategic Collaboration to Apply Cancer Genomics to Discover and Develop Next Generation Cancer Therapeutics
11. United Therapeutics Receives Paragraph IV Notice Letter for Remodulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... , Oct. 4, 2017 ... single-use, self-contained, illuminating medical devices, today announced regulatory ... Health Surveillance Agency (or Agência Nacional de Vigilância ... first single-use, cordless surgical retractor with integrated LED ... optimal access, illumination and exposure of a tissue ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
Breaking Medicine News(10 mins):